阿托伐他汀与氯吡格雷对不稳定型心绞痛患者白介素6、超敏C反应蛋白及预后的影响(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨阿托伐他汀与氯吡格雷对不稳定型心绞痛患者的疗效和对白介素6(IL-6)、超敏C反应蛋白(hs-CRP)及预后的影响。 方法 将68例患者分为观察组(常规治疗+阿托伐他汀与氯吡格雷)36例和对照组32例(常规治疗)，比较两组治疗后心绞痛症状改善程度及治疗后心电图改善情况及IL-6、hs-CRP变化、心血管事件发生率。 结果 观察组治疗后心绞痛症状改善的总有效率(91.67%)明显高于对照组(78.13%)，且观察组患者心绞痛持续时间明显短于对照组(P < 0.05)。治疗后观察组心电图的总有效率(94.44%)明显高于对照组(81.25%)(P < 0.05)。观察组治疗后TC、TG、IL-6、hs-CRP明显低于对照组(均P < 0.05)。观察组总心血管事件发生率为5.56%，明显低于对照组(21.88%)(P < 0.01)。结论 阿托伐他汀联合氯吡格雷治疗不稳定型心绞痛疗效确切，心血管事件发生率低，考虑可能是通过阻断hs-CRP的生成，降低血清hs-CRP、IL-6的水平抑制其促炎效应，从而减少心肌梗死的发生。
[关键词] 不稳定型心绞痛；阿托伐他汀；氯吡格雷；白介素6；超敏C反应蛋白；预后
[中图分类号] R541 [文献标识码] A [文章编号] 1673-7210(2012)02(a)-0054-03
Impact of Atorvastatin and Clopidogrel treatment in patients with unstable angina on IL-6 and hs-CRP and prognosis
WANG Zhi LIU Ye
Department of Critical Care Medicine, the 208th Hospital of PLA, Jilin Province, Changchun 130062, China
[Abstract] Objective To investigate the efficacy of Atorvastatin and Clopidogrel for the patients with unstable angina，and to explore the impact on IL-6，hs-CRP and prognosis. Methods All 68 patients were divided into observation group (conventional therapy and Atorvastatin and Clopidogrel) 36 cases and the control group 32 patients (conventional treatment)，and after treatment, the improvement degree of angina symptoms and ECG and IL-6, hs-CRP changes and the incidence rates of cardiovascular events were compared. Results The overall efficiency of angina symptoms which improved (91.67%) was significantly higher than the control group (78.13%). And the duration of the observation group was significantly shorter than the control group (P < 0.05). ECG response rate of the observation group (94.44%) was significantly higher than the control group (81.25%) (P < 0.05). After treatment, the level of TC, TG, IL-6, hs-CRP of the observation group was significantly lower than the control group (all P < 0.05). The total cardiovascular events incidence rate of the observation group (5.56%) was significantly lower than the control group (21 ......
您现在查看是摘要介绍页，详见PDF附件(2343kb)。